Shravan Gangula, MD
Family Medicine · Coffeyville, KSNPI 1437463593
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $960, 2.7 times the $355 reported in 2019.
Across 271 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$873
- AstraZeneca$599
- Bayer$414
- Merck$400
- Sanofi-aventis U.S. LLC$257
- Lilly USA, LLC$233
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,18596%
- Education$1554%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $873 |
| AstraZeneca | 37 | $599 |
| Bayer | 26 | $414 |
| Merck | 24 | $400 |
| Sanofi-aventis U.S. LLC | 17 | $257 |
| Lilly USA, LLC | 15 | $233 |
| Pfizer | 11 | $186 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $137 |
| Teva Pharmaceuticals USA, Inc. | 3 | $126 |
| Amgen | 6 | $111 |
| Johnson & Johnson | 8 | $110 |
| GSK | 6 | $105 |
| Xeris Pharmaceuticals, Inc. | 5 | $84 |
| Boehringer Ingelheim | 5 | $78 |
| Novo Nordisk | 5 | $74 |
| Smith+Nephew | 5 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| Verona Pharma, Inc. | 2 | $44 |
| Stryker | 1 | $44 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $37 |
| Abbott | 2 | $37 |
| Acadia Pharmaceuticals Inc | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Novartis | 2 | $29 |
| Cardinal Health 200 LLC | 1 | $21 |
| Vertex | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Convatec Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Ardelyx, Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$4,340 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 286 | $225,255 |
| TrulicityDulaglutide | 154 | $166,046 |
| IngrezzaValbenazine Tosylate | 29 | $145,287 |
| JanuviaSitagliptin Phosphate | 169 | $135,404 |
| EliquisApixaban | 253 | $124,395 |
| OzempicSemaglutide | 82 | $83,658 |
| LinzessLinaclotide | 122 | $70,649 |
| MounjaroTirzepatide | 65 | $70,388 |
| KerendiaFinerenone | 72 | $60,602 |
| XareltoRivaroxaban | 76 | $59,929 |
| JardianceEmpagliflozin | 77 | $52,200 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $41,894 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $36,684 |
| MyrbetriqMirabegron | 55 | $34,620 |
| QuliptaAtogepant | 20 | $32,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $599 | $274,457368 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $233 | $236,434219 claims |
| AbbVieLinzess, Qulipta, Vraylar, Namzaric, Savella | $873 | $142,732200 claims |
| PfizerEliquis, Premarin | $186 | $135,867284 claims |
| MerckJanuvia | $400 | $135,404169 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $78 | $91,846149 claims |
| Novo NordiskOzempic | $74 | $83,65882 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta, Arexvy | $105 | $68,874150 claims |
| BayerKerendia | $414 | $60,60272 claims |
| Johnson & JohnsonXarelto | $110 | $59,92976 claims |
| AmgenOtezla | $111 | $28,93212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Coffeyville
- Bradley HarrisonManhattan$314K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Kent KiracofeManhattan$189K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Kyle PlatzManhattan$51K
- Eric AspinwallKansas City$28K
- Hai TruongWichita$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.